Top Suppliers:I want be here




190786-44-8

190786-44-8 structure
190786-44-8 structure
  • Name: Bepotastine Besilate
  • Chemical Name: bepotastine besylate
  • CAS Number: 190786-44-8
  • Molecular Formula: C27H31ClN2O6S
  • Molecular Weight: 547.063
  • Catalog: API Antineoplastic agents Alkylating agent
  • Create Date: 2018-06-12 16:35:15
  • Modify Date: 2024-01-05 10:46:53
  • Bepotastine Beslilate (Bepreve) is a histamine H1 receptor anatagonist. IC50 value:Target: Histamine H1 receptorBepotastine Beslilate (Bepreve) also suppresses some allergic inflammatory processes such as allergic rhinitis, chronic urticaria or pruritus associated with skin conditions (eczema/dermatitis, prurigo or pruritus cutaneus).Bepotastine Beslilate (Bepreve) is useful for allergic conjunctivitis.

Name bepotastine besylate
Synonyms Bepotastine benzenesulfonate salt
UNII:6W18MO1QR3
Bepotastine Besilate
benzenesulfonic acid,4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
4-{4-[(S)-(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate
4-{4-[(S)-(4-Chlorophenyl)(2-pyridinyl)methoxy]-1-piperidinyl}butanoic acid benzenesulfonate (1:1)
Talion
Bepotastine besylate
UNII-6W18MO1QR3
TAU-284
Bepotastine benzenesulfonate
Betotastine besilate
1-Piperidinebutanoic acid, 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-, benzenesulfonate (1:1)
Bepotastine (Beslilate)
Bepreve
4-{4-[(S)-(4-Chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-yl}butanoic acid benzenesulfonate (1:1)
Description Bepotastine Beslilate (Bepreve) is a histamine H1 receptor anatagonist. IC50 value:Target: Histamine H1 receptorBepotastine Beslilate (Bepreve) also suppresses some allergic inflammatory processes such as allergic rhinitis, chronic urticaria or pruritus associated with skin conditions (eczema/dermatitis, prurigo or pruritus cutaneus).Bepotastine Beslilate (Bepreve) is useful for allergic conjunctivitis.
Related Catalog
References

[1]. Cho KH, Choi HG.Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs.Drug Dev Ind Pharm. 2012 Sep 10.

[2]. Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI; for the Bepotastine Besilate Ophthalmic Solutions Study Group.Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic con

[3]. Kawakami T, Kimura S, Haga T, Doi R, Kyoya M, Nakagawa K, Soma Y.Health-related quality of life assessed by the effect of bepotastine besilate in patients with pruritus: importance of emotions score in atopic dermatitis.J Dermatol. 2012 Jun;39(6):527-30.

[4]. Williams JI, Kennedy KS, Gow JA, Torkildsen GL, Abelson MB, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Study Group.Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic c

[5]. Kida, Tetsuo; Fujii, Atsuko; Sakai, Osamu; Iemura, Masahito; Atsumi, Ikuyo; Wada, Tomoyuki; Sakaki, Hideyuki. Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in i

Boiling Point 546.8ºC at 760 mmHg
Melting Point 161-163°
Molecular Formula C27H31ClN2O6S
Molecular Weight 547.063
Flash Point 284.5ºC
Exact Mass 546.159119
PSA 125.41000
LogP 6.12220
Vapour Pressure 8.63E-13mmHg at 25°C
Hazard Codes Xi